Literature DB >> 22226119

Neuroblastoma: issues in transplantation.

Stephan A Grupp1, Shahab Asgharzadeh, Gregory A Yanik.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22226119      PMCID： PMC3260463          DOI： 10.1016/j.bbmt.2011.10.020

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  75 in total

1.  Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.

Authors:  Katleen De Preter; Joëlle Vermeulen; Benedikt Brors; Olivier Delattre; Angelika Eggert; Matthias Fischer; Isabelle Janoueix-Lerosey; Cinzia Lavarino; John M Maris; Jaume Mora; Akira Nakagawara; André Oberthuer; Miki Ohira; Gudrun Schleiermacher; Alexander Schramm; Johannes H Schulte; Qun Wang; Frank Westermann; Frank Speleman; Jo Vandesompele
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Authors:  Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

3.  Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.

Authors:  David L Baker; Mary L Schmidt; Susan L Cohn; John M Maris; Wendy B London; Allen Buxton; Daniel Stram; Robert P Castleberry; Hiroyuki Shimada; Anthony Sandler; Robert C Shamberger; A Thomas Look; C Patrick Reynolds; Robert C Seeger; Katherine K Matthay
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

Review 4.  Global genomic and RNA profiles for novel risk stratification of neuroblastoma.

Authors:  Miki Ohira; Akira Nakagawara
Journal:  Cancer Sci       Date:  2010-11       Impact factor: 6.716

5.  Prognostic impact of gene expression-based classification for neuroblastoma.

Authors:  André Oberthuer; Barbara Hero; Frank Berthold; Dilafruz Juraeva; Andreas Faldum; Yvonne Kahlert; Shahab Asgharzadeh; Robert Seeger; Paola Scaruffi; Gian Paolo Tonini; Isabelle Janoueix-Lerosey; Olivier Delattre; Gudrun Schleiermacher; Jo Vandesompele; Joëlle Vermeulen; Frank Speleman; Rosa Noguera; Marta Piqueras; Jean Bénard; Alexander Valent; Smadar Avigad; Isaac Yaniv; Axel Weber; Holger Christiansen; Richard G Grundy; Katharina Schardt; Manfred Schwab; Roland Eils; Patrick Warnat; Lars Kaderali; Thorsten Simon; Boris Decarolis; Jessica Theissen; Frank Westermann; Benedikt Brors; Matthias Fischer
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 44.544

Review 6.  Neuroblastoma.

Authors:  John M Maris; Michael D Hogarty; Rochelle Bagatell; Susan L Cohn
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

7.  Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.

Authors:  Janine Stutterheim; Annemieke Gerritsen; Lily Zappeij-Kannegieter; Bilgehan Yalcin; Rob Dee; Max M van Noesel; Frank Berthold; Rogier Versteeg; Huib N Caron; C Ellen van der Schoot; Godelieve A M Tytgat
Journal:  Clin Chem       Date:  2009-05-21       Impact factor: 8.327

8.  Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.

Authors:  Thorsten Simon; Barbara Hero; Andreas Faldum; Rupert Handgretinger; Martin Schrappe; Thomas Klingebiel; Frank Berthold
Journal:  BMC Cancer       Date:  2011-01-18       Impact factor: 4.430

9.  Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.

Authors:  K Beiske; S A Burchill; I Y Cheung; E Hiyama; R C Seeger; S L Cohn; A D J Pearson; K K Matthay
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

10.  International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.

Authors:  P F Ambros; I M Ambros; G M Brodeur; M Haber; J Khan; A Nakagawara; G Schleiermacher; F Speleman; R Spitz; W B London; S L Cohn; A D J Pearson; J M Maris
Journal:  Br J Cancer       Date:  2009-05-05       Impact factor: 7.640
View more
  5 in total

1.  Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.

Authors:  Aimee C Talleur; Brandon M Triplett; Sara Federico; Ewelina Mamcarz; William Janssen; Jianrong Wu; David Shook; Wing Leung; Wayne L Furman
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-18       Impact factor: 5.742

Review 2.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Authors:  Nai-Kong V Cheung; Michael A Dyer
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

3.  Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

Authors:  Brian H Kushner; Irina Ostrovnaya; Irene Y Cheung; Deborah Kuk; Shakeel Modak; Kim Kramer; Stephen S Roberts; Ellen M Basu; Karima Yataghene; Nai-Kong V Cheung
Journal:  Oncotarget       Date:  2016-01-26

4.  MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

Authors:  Brian H Kushner; Michael P LaQuaglia; Shakeel Modak; Suzanne L Wolden; Ellen M Basu; Stephen S Roberts; Kim Kramer; Karima Yataghene; Irene Y Cheung; Nai-Kong V Cheung
Journal:  Oncotarget       Date:  2017-08-24

5.  Cancer stem cells in neuroblastoma therapy resistance.

Authors:  Natarajan Aravindan; Drishti Jain; Dinesh Babu Somasundaram; Terence S Herman; Sheeja Aravindan
Journal:  Cancer Drug Resist       Date:  2019-11-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.